Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) Appoints Carolyn Taylor To Its Board and releases Q1 2021 Result

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) has appointed Carolyn Taylor as a board member effective July 16, 2021. 

Tonix appoints Carolyn Taylor to its Board. 

Taylor has been a Covington & Burling law firm partner for over 15 years and has served as General Counsel of Longitude Inc. and Strike Protocols. She said, “It’s a pleasure to join a company with a strong sense of purpose coupled with such a dedicated, experienced management team. I look forward to collaborating with the management team and the other members of Tonix’s Board as well as offering my perspective on Tonix’s strategic initiatives.”

Commenting on the appointment, CEO Seth Lederman said, “We are pleased to welcome Carolyn E. Taylor to the Tonix Board. Ms. Taylor brings over 35 years of experience in corporate law, including 15 years as a partner at Covington & Burling LLP and six years as general counsel of two start-up companies. Her broad-based transactional experience will be invaluable to Tonix as we continue to grow the company. We look forward to the insights Ms. Taylor will bring to the Board.”

Tonix expects three CNS programs to enter phase two trials. 

Recently the company released its Q1 2021 financial results and offered an operational update. Tonix has an expansive pipeline of high-value programs that range from preclinical to mod-phase development programs, with 3 CNS programs expected to enter second phase studies this year. The company’s strategy is in-licensing, acquiring, or inventing high-impact therapies to de-risk, validate, and advance clinical development. 

Lederman commented, “Our clinical, manufacturing, and regulatory teams are progressing programs across multiple modalities including small molecule drugs, synthetic peptides, biologics, monoclonal antibodies and live virus vaccines.” The company’s three CNS products entering second phase trials include TNX 1300, TNX1900, and TNX-601 CR. The company’s most advanced program is the third phase confirmatory TNX-102 SL study for fibromyalgia management.